Replimune logo

Replimune

REPL | NASDAQ
Chart Builder DCF Calculator
$21.41
-$0.48 (-2.19%)
At close: Nov 16, 2026, 4:00 PM ET
$21.33
-$0.08 (-0.37%)
After-hours: Nov 16, 2026, 7:48 PM ET
-2.19%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
26.1
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #900/1021 (Top 88%)

Key Statistics

Market Data

Market Cap $2.25B
1D Range
21.18 22.00
52W Range
1.70 23.28

Valuation (TTM)

PE -7.67
PB 11.00
EV/EBITDA -8.00

Valuation (NTM)

Forward PE N/A
Forward PEG 0.27
Price Target $24.50
Loading financial charts...

Profile

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platf...

Sector Healthcare
Industry Biotechnology
Employees 465
IPO Date Jul 20, 2018
Fiscal Year April - March

Latest News

REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress

4 days ago · zacks.com

REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress
Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade

15 days ago · zacks.com

Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
Replimune: 3 Key Takeaways for Long-Term Investors

19 days ago · fool.com

Replimune: 3 Key Takeaways for Long-Term Investors
Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript

19 days ago · seekingalpha.com

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

20 days ago · globenewswire.com

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

26 days ago · globenewswire.com

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

2 months ago · globenewswire.com

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript

2 months ago · seekingalpha.com

Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago · globenewswire.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

3 months ago · globenewswire.com

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Earnings

Next Earnings
Feb 2, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$24.50
Upside
+14.43%
Buy (5)
Hold (1)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.